GW0742 + SR9011 is offered in 2 variants: 10mg GW0742 and 10mg SR9011, totaling 20mg per tablet for 27 tablets or 540mg in total: 10mg GW0742 and 10mg SR9011, totaling 20mg per tablet for 54 tablets or 1080mg in total.
GW0742 is a PPARβ/δ agonist that has been shown to improve glucose homeostasis and insulin sensitivity in diabetic rats, as well as increase fat loss. Treatment with GW0742 has also been shown to improve dyslipidemia and hyperglycemia in diet-induced obese mice. The activation of PPARβ/δ by GW0742 leads to enhanced circadian rhythm, which affects behaviour, sleep cycle and some functions related to increment in energy production.
|IUPAC Name||2-[4-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid|
|Molar Mass||479.04 g·mol−1|